TIGIT and cancer: Dual blockade of TIGIT and PD-1 resulted in the restoration of T-cell immunity in preclinical settings and provided a rationale for combination with these agents as a feasible anti-cancer therapeutic strategy (Johnston et al., 2014; Kurtulus et al., 2015; Zhang et al., 2018).